Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
or

Biohaven Ltd (BHVN)

Biohaven Ltd (BHVN)
40.56 +1.53 (+3.92%) 01/22/25 [NYSE]
39.11 x 100 40.92 x 100
Realtime by (Cboe BZX)
39.11 x 100 40.92 x 100
Realtime 40.56 unch (unch) 16:31 ET
Quote Overview for Wed, Jan 22nd, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
38.96
Day High
40.75
Open 39.03
Previous Close 39.03 39.03
Volume 1,074,012 1,074,012
Avg Vol 1,138,601 1,138,601
Stochastic %K 76.16% 76.16%
Weighted Alpha -8.82 -8.82
5-Day Change +4.99 (+14.03%) +4.99 (+14.03%)
52-Week Range 26.80 - 62.21 26.80 - 62.21
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 3,946,792
  • Shares Outstanding, K 101,122
  • Annual Sales, $ 0 K
  • Annual Income, $ -408,170 K
  • EBIT $ -849 M
  • EBITDA $ -842 M
  • 60-Month Beta 1.29
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 11.25

Options Overview Details

View History
  • Implied Volatility 58.37% ( -4.03%)
  • Historical Volatility 59.62%
  • IV Percentile 0%
  • IV Rank 5.64%
  • IV High 138.64% on 05/24/24
  • IV Low 53.57% on 08/16/24
  • Put/Call Vol Ratio 0.23
  • Today's Volume 504
  • Volume Avg (30-Day) 1,091
  • Put/Call OI Ratio 0.84
  • Today's Open Interest 14,400
  • Open Int (30-Day) 19,792

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 15 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -1.53
  • Number of Estimates 9
  • High Estimate -0.56
  • Low Estimate -2.01
  • Prior Year -1.81
  • Growth Rate Est. (year over year) +15.47%

Price Performance

See More
Period Period Low Period High Performance
1-Month
34.20 +18.60%
on 01/13/25
Period Open: 36.26
40.75 -0.47%
on 01/22/25
+4.30 (+11.86%)
since 12/20/24
3-Month
34.20 +18.60%
on 01/13/25
Period Open: 52.65
54.98 -26.23%
on 11/06/24
-12.09 (-22.96%)
since 10/22/24
52-Week
26.80 +51.34%
on 05/29/24
Period Open: 48.45
62.21 -34.80%
on 03/08/24
-7.89 (-16.28%)
since 01/22/24

Most Recent Stories

More News
Biohaven Stock Surges After Director Acquires Shares Worth Over $1M: Retail Sentiment Turns Bullish

Earlier this month, Biohaven reported achieving important milestones in the trial of its experimental drug BHV-1300, which is intended for use in the treatment of kidney disease.

BHVN : 40.56 (+3.92%)
Biohaven’s SMA Trial Miss Bolsters Scholar Rock Stock: Analysts Give Verdicts, Retail Watches Closely

Last month, Scholar Rock achieved the primary endpoint in the company's own Phase 3 trial of apitegromab in SMA patients.

BHVN : 40.56 (+3.92%)
VTI : 300.60 (+0.49%)
SRRK : 46.73 (+4.12%)
IWM : 228.29 (-0.65%)
XBI : 91.21 (+0.77%)
SRRK Stock Soars as Muscle Disease Drug Meets Phase III Study Goal

Shares of Scholar Rock SRRK skyrocketed 362% on Monday after the company announced positive top-line results from the late-stage study, evaluating the efficacy and safety of its investigational muscle-targeted...

BHVN : 40.56 (+3.92%)
ANIP : 58.16 (-0.33%)
CPRX : 22.87 (-0.22%)
SRRK : 46.73 (+4.12%)
BHVN Stock Up as Rare Neurological Disease Study Meets Primary Goal

Shares of Biohaven Ltd. BHVN were up 13.7% on Sept. 23 after the company announced positive top-line data from the pivotal BHV4157-206-RWE study, which evaluated its pipeline candidate, troriluzole, for...

BHVN : 40.56 (+3.92%)
KRYS : 153.46 (+1.26%)
FULC : 4.09 (+2.25%)
ANIP : 58.16 (-0.33%)
Biohaven Stock Soars on Drug Trial Results: Time to Jump In?

Biohaven, a clinical-stage biopharmaceutical company, is attracting investors with promising results for its experimental drug.

BHVN : 40.56 (+3.92%)
Canada Jobs in Focus Next Week

Monday U.S. Featured Earnings Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) (Q1) EPS of $3.66, ...

VRTX : 428.00 (+0.03%)
MCHP : 58.48 (-0.05%)
PLTR : 76.87 (+5.20%)
DIS : 108.81 (+0.10%)
ANET : 129.82 (+6.85%)
TM : 186.52 (-0.22%)
UBER : 67.82 (+0.12%)
ABNB : 132.50 (-0.43%)
HMC : 28.45 (-0.87%)
CEG : 332.47 (+2.73%)
RBLX : 66.00 (-0.15%)
BHVN : 40.56 (+3.92%)
Biohaven Presents Preclinical Data Demonstrating Taldefgrobep alfa Reduces Fat and Improves Lean Mass at The Obesity Society's Annual Meeting, ObesityWeek®

- Taldefgrobep is a novel myostatin inhibitor with the potential to be an important therapy for neuromuscular disorders and metabolic diseases including...

BHVN : 40.56 (+3.92%)
Biohaven Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares

/PRNewswire/ -- Biohaven Ltd. (NYSE: BHVN), a global clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of...

BHVN : 40.56 (+3.92%)
Markets Today: Stocks Decline as Bond Yields Soar

Morning Markets December E-Mini S&P 500 futures (ESZ2 3) are down -0.61%, and the Dec Nasdaq 100 E-Mini futures (NQZ2 3) are down -0.76%. Stock index futures this morning are moderately lower, weighed...

ESH25 : 6,120.50s (+0.60%)
NQH25 : 22,000.50s (+1.34%)
MCK : 584.38 (-0.29%)
BHVN : 40.56 (+3.92%)
ABNB : 132.50 (-0.43%)
KLG : 16.86 (+0.30%)
HPQ : 33.13 (+0.55%)
DOW : 40.82 (-1.83%)
LYB : 77.08 (-0.84%)
FVRR : 32.06 (-2.70%)
DY : 191.89 (-1.46%)
PNT : 12.50 (+0.16%)
Biohaven Announces Pricing of $225 Million Public Offering of Common Shares

/PRNewswire/ -- Biohaven Ltd. (NYSE: BHVN), a global clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of...

BHVN : 40.56 (+3.92%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Sell with a Weakest short term outlook on maintaining the current direction.

See More Share

Business Summary

Biohaven Ltd. is a clinical-stage biopharmaceutical company. It focuses on discovering and developing therapies for patients with debilitating neurological and neuropsychiatric diseases principally in the United States. Biohaven Ltd., formerly known as BIOHAVEN PHARM, is based in New Haven, Connecticut....

See More

Key Turning Points

3rd Resistance Point 43.01
2nd Resistance Point 41.88
1st Resistance Point 41.22
Last Price 40.56
1st Support Level 39.43
2nd Support Level 38.30
3rd Support Level 37.64

See More

52-Week High 62.21
Fibonacci 61.8% 48.68
Fibonacci 50% 44.50
Last Price 40.56
Fibonacci 38.2% 40.33
52-Week Low 26.80

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar